Duke at. American Society of Clinical Oncology Chicago, Illinois
|
|
- Ira Lloyd
- 6 years ago
- Views:
Transcription
1 Duke at American Society of Clinical Oncology 2017 Chicago, Illinois
2 Duke Medicine Divisions of Hematology Medical Oncology and Hematologic Malignancy & Cellular Therapy Cordially invite you to the Duke reception in conjunction with the ASCO Annual Meeting in Chicago, Illinois Saturday, June 3, :00 p.m. 9:00 p.m. The Hyatt Regency Chicago 151 East Wacker Drive Comiskey Room
3 Conquer Cancer Foundation/AstraZeneca Young Investigator Award Nicholas C. DeVito, MD Duke University Medical Center Investigating Oncogenic Signaling Pathways that Drive Wnt Ligandmediated Immune Tolerance in Melanoma Mentored by: Brent Hanks, MD, PhD
4 Cancer Education Committee Geriatric Oncology Gretchen Kimmick, MD Head and Neck Cancer Joseph K. Salama, MD Health Services Research, Clinical Informatics, and Quality of Care Yousuf Zafar, MD, MHS Scientific Program Committee Biostatistics Susan Halabi, PhD Genitourinary (Nonprostate) Cancer Daniel J. George, MD Patient and Survivor Care Chair-elect, Ethics Committee Scientific Track Chair, Patient and Survivor Care Member, ASCO Taxonomy Subcommittee Thomas LeBlanc, MD, MA Tumor Biology Andrew Nixon, PhD Educational Book: Zhang, T., Gong, J., Caitano, M., Pal, S.K. Systemic therapy for non-clear cell renal cell carcinoma. In ASCO 2017 Educational Book. e Abstract Title: Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer. Andrew Armstrong, MD
5 Friday, June 2, :45 PM - 4:15 PM Location: Arie Crown Theater Clinical Science Symposium Expanding the Actionable Landscape: Bladder Cancer Genomics Track(s): Genitourinary (Nonprostate) Cancer Chair(s): Tian Zhang, MD 1:00 PM - 3:15 PM Location: Location: S504 Extended Education Session Moving Beyond the Randomized Controlled Trial: Real-World Data to Inform Patient Care and Policy Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Clinical Trials; Patient and Survivor Care; Pediatric Oncology; Value PCORnet: A Developing Data Source by Linking Electronic Medical Records Lesley H. Curtis - Speaker Saturday, June 3, :00 AM - 9:15 AM Location: E450ab Education Session Endometrial Cancers of Young and Older Patients: New Observations and Perspectives Track(s): Gynecologic Cancer; Cancer Prevention, Hereditary Genetics, and Epidemiology; Geriatric Oncology; Patient and Survivor Care The Roles of Exercise in Risk Reduction Kathryn Elizabeth Hudson - Speaker 8:00 AM - 11:00 AM Location: S103 Extended Education Session Designing Clinical Trials for an Aging Population Track(s): Geriatric Oncology; Clinical Trials; Disparities; Patient and Survivor Care Chair(s): Gretchen Genevieve Kimmick, MD, MS 8:00 AM - 11:30 AM Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer Abstract TPS3624 A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mcrc)(mountaineer). Poster Board: #244a John H. Strickler - First Author
6 Saturday continued 1:15 PM - 4:45 PM Poster Discussion Session Tumor Biology Track(s): Tumor Biology Chair(s): Andrew B. Nixon, PhD Tumor Biology Track(s): Tumor Biology Abstract Biomarker modulation in patients treated with TRC105 in combination with anti-vegf therapy. Poster Board: #246 Yingmiao Liu - First Author Patient and Survivor Care Track(s): Patient and Survivor Care Abstract Risk tolerance and attitudes toward chemotherapy: Who chooses palliative treatment when cure is possible? Poster Board: #43 Thomas William LeBlanc, MD, MA, MHS - First Author Abstract Survivorship needs after head and neck cancer treatment. Poster Board: #51 Callie Berkowitz - First Author Gynecologic Cancer Track(s): Gynecologic Cancer Abstract 5544 Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO s net health benefits (NHB) inform our decisions? Poster Board: #366 Jonathan Foote - First Author Abstract 5571 Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer. Poster Board: #393 Stephanie Gaillard - First Author Abstract TPS10128 Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET) Poster Board: #115a Gretchen Genevieve Kimmick - First Author Saturday continued Location: Hall B1 Oral Abstract Session
7 Genitourinary (Prostate) Cancer Track(s): Genitourinary (Prostate) Cancer Abstract 5006 Phase 3 prognostic analysis of the automated bone scan index (absi) in men with bone-metastatic castrationresistant prostate cancer (CRPC). Andrew J. Armstrong - First Author Interpreting Biomarkers and Trial Outcomes: How Confident Are We? Susan Halabi - Discussant 1:15 PM - 2:30 PM Location: Arie Crown Theater Poster Discussion Session Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer PET to Plasma: Evolution of Disease Monitoring John H. Strickler - Discussant 4:45 PM - 6:00 PM Location: S404 Poster Discussion Session Patient and Survivor Care Track(s): Patient and Survivor Care Communication, Coping, and Cancer, Discussing Abstract(s): 10021, 10022, Thomas William LeBlanc - Discussant Sunday, June 4, :00 AM - 9:15 AM Location: S504 Is the Sharper Knife Worth the Price? A Discussion of Protons Versus Photons Track(s): Head and Neck Cancer; Value Is the Sharper Knife Worth the Price: Intensity-Modulated Radiation Therapy (Proton Versus Intensity- Modulated Radiation Therapy) David M. Brizel - Speaker 8:00 AM - 9:15 AM Location: S100bc Education Session Starting the Conversation: Interventions to Reduce Financial Toxicity Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Disparities; Ethics; Value Chair(s): Yousuf Zafar, MD, MHS
8 Sunday continued 8:00 AM - 8:05 AM Overview of Financial Toxicity. Yousuf Zafar, MD, MHS - Chair 8:00 AM - 11:30 AM Poster Discussion Session Genitourinary (Nonprostate) Cancer Track(s): Genitourinary (Nonprostate) Cancer Abstract 4522 Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB (Alliance). Poster Board: #200 Daniel J. George - First Author Breast Cancer Local/Regional/Adjuvant Track(s): Breast CancerAbstract 532 A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients. Poster Board: #132 Cecilia Tuongquang Ong - First Author Abstract 554 Role of axillary node dissection after mastectomy with positive sentinel nodes. Poster Board: #154 Tristen Sinae Park - First Author 8:00 AM - 9:30 AM Location: Hall B1 Clinical Science Symposium Old Targets, New Drugs: HER2 and MET Track(s): Lung Cancer; Lung Cancer Abstract 8509 Efficacy, safety, and biomarker results of trastuzumab emtansine (TDM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mnsclc). Tom Stinchcombe - First Author 9:45 AM - 12:45 PM Location: E354b Oral Abstract Session Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Abstract 8008 Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma. Dharshan Sivaraj - First Author
9 Monday, June 5, :00 AM - 11:00 AM Location: S100bc Oral Abstract Session Health Services Research, Clinical Informatics, and Quality of Care Track(s): Health Services Research, Clinical Informatics, and Quality of Care 10:12 AM - 10:24 AM Abstract 6507 Implementation of precision oncology in the Veterans Health Administration (VHA). Michael J. Kelley, MD - First Author Department of Veterans Affairs 8:00 AM - 11:30 AM Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Abstract 8023 Impact of t(11;14) on outcomes in African American (AA) and non-aa (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry. Poster Board: #349 Cristina Gasparetto - First Author Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Track(s): Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Abstract 7538 Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. Poster Board: #300 Joanne Soo - First Author 1:15 PM - 4:45 PM Genitourinary (Prostate) Cancer Track(s): Genitourinary (Prostate) Cancer Abstract 5022 Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mcrpc) from the phase 3 prevail clinical trial. Poster Board: #96 Andrew J. Armstrong - First Author
10 Monday continued Central Nervous System Tumors Track(s): Central Nervous System Tumors Abstract 2049 Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries. Poster Board: #291 Jessie Narloch - First Author (Dr. Kimberly Blackwell) Cancer Prevention, Genetics, and Epidemiology Track(s): Cancer Prevention, Hereditary Genetics, and Epidemiology Abstract 1570 The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database. Poster Board: #228 Brittany Morgan Campbell - First Author 1:15 PM - 4:45 PM Health Services Research, Clinical Informatics, and Quality of Care Track(s): Health Services Research, Clinical Informatics, and Quality of Care Abstract 6532 Impact of insurance status on treatment for stage 0-IV breast cancer. Poster Board: #354 Rachel Adams Greenup - First Author Health Services Research, Clinical Informatics, and Quality of Care Track(s): Health Services Research, Clinical Informatics, and Quality of Care Abstract 6608 Cost-effectiveness of ovarian cancer screening: An analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) from a U.S. health system perspective. Poster Board: #430 Haley Moss - First Author
PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationLudwig Presence at 2016 ASCO Annual Meeting
Ludwig Scientist(s) Affiliation(s) Session and Presentation Time Location Track Session Type/Title Presentation and/or Abstract Title Friday, June 3, 2016 Luisa Lina Villa Ludwig Sao Paulo 1:00pm - 3:15pm
More informationRoche Investor Relations ASCO Planner 2017
Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi,
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationRoche Investor Relations ASCO Planner 2018
Roche Investor Relations ASCO Planner 2018 Friday, June 1 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Date: Fri, June 1 Time: 2:45 PM - 5:45 PM Speaker Name: Luciano J. Costa 3:57 PM
More informationSteamboat Springs, Colorado. January 15-18, 2016
Friday, January 15, 2016 Registration: Begins at 2:00 pm Plenary Session: 4:00 pm - 6:00 pm 14 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 15-18, 2016 Current Status
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationPLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018
PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, 2018 16 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 12-15, 2018 Friday, January 12, 2018 Registration:
More informationNCIC Clinical Trials Group ASCO Annual Meeting Presentations
Saturday, June 1 Session Title: Central Nervous System Tumors IND.204 - Poster Board: #3A Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2053) Marshall W. Pitz, MD FRCPC Session Title:
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationRoche Investor Relations ASCO Planner 2015
Roche Investor Relations ASCO Planner 2015 Saturday, May 30 Session Title: Developmental Therapeutics Immunotherapy Poster Board: #341 Molecular, immune and histopathological characterization of NSCLC
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationCONFERENCE AGENDA (Subject to Change)
Thursday, August 9, 2018 7:00 am 5:30 pm Registration Desk Open 8:00 am 8:10 am Welcome and Announcements 8:10 am 9:00 am Best of ASCO Session 1 Genitourinary Cancer 9:00 am 9:50 am Best of ASCO Session
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationAction to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research
Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationChemotherapy for Urological Cancers
Chemotherapy for Urologic Cancers Matthew Rettig, MD Associate Professor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, Prostate Cancer Program Institute
More informationSupplemental Table 1.1: Prostate cancer prognostic tools
Supplemental Table 1.1: Prostate cancer prognostic tools Features ANN^ BioChemical Capra^ CSQS EBRT Han Outcomes Cancer Specific - - +* + - - Non-Cancer Specific - - - + - - DFS/PFS +* +* +* - +* +* Clinical
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration
More informationSession II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair
Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Symposium: Innovation in Breast Cancer 2014 Madrid, Spain February 21, 2014 Cancer
More informationThursday, August 9, :00 am 5:30 pm Registration Desk Open Atlantic Ballroom Foyer. 7:00 am 8:00 am Continental Breakfast Atlantic Ballroom Foyer
Thursday, August 9, 2018 7:00 am 5:30 pm Registration Desk Open 7:00 am 8:00 am Continental Breakfast 8:00 am 8:10 am Welcome and Announcements 8:10 am 9:00 am Best of ASCO 1: Genitourinary Cancer Speaker:
More informationOncology Drug Development Using Molecular Pathology
Oncology Drug Development Using Molecular Pathology Introduction PRESENTERS Lee Schacter, PhD, MD, FACP Executive Medical Director, Oncology Clinipace Worldwide Martha Bonino Director, Strategic Accounts
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationHall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
More informationRoche Investor Relations ASCO Planner 2014
Roche Investor Relations ASCO Planner 2014 F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations email: investor.relations@roche.com Tel. +41 61 68-88880 Fax +41 61 69-10014 www.roche.com
More informationESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14
More information2016 ASCO Annual Meeting
UNIVERSITY OF CHICAGO PRESENTATIONS THURSDAY JUNE 2 1:00 pm-2:50 pm The Economics of Cancer Care Seminar Session I: Innovative Cancer Treatment Models: Theory, Evidence and Practice Outpatient Oncology
More informationFOCUS ON NEUROENDOCRINE TUMORS 8 TH ANNUAL. Friday, March 8, am 2:30 pm. REGISTER ONLINE AT PennMedicine.org/Abramson/NETs
8 TH ANNUAL FOCUS ON NEUROENDOCRINE TUMORS A PATIENT & CAREGIVER PROGRAM Friday, March 8, 2019 8 am 2:30 pm REGISTER ONLINE AT PennMedicine.org/Abramson/NETs Attend in Person or View Livestream OPEN TO
More informationHematology, Oncology & Blood & Marrow Transplant for NPs & PAs
PHARMACOLOGY CONTENT Hematology, Oncology & Blood & Marrow Transplant for NPs & PAs Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately
More informationB. Mark Evers, MD Director, Markey Cancer Center University of Kentucky
April 13 Time Topic Speaker 8-8:30 Welcomes Robert DiPaola, MD, PhD Dean, College of Medicine B. Mark Evers, MD Director, Markey Cancer Center 8:30-9:00 Overview of Immunology and Basis of Immunotherapy
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationTuesday 25th October
14.00-1700 Tuesday 25th October Registration Open Welcome reception Wednesday 26th October 1 - In Situ Disease and Screening Current perspectives on the classification and significance of in situ carcinoma
More informationAn update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute
An update on your support of the Swedish Cancer Institute At Swedish, we re committed to offering our patients the newest, most innovative cancer treatment available. Through your support of the at the
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationChallenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationSummary... 2 GENITOURINARY TUMOURS - PROSTATE... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationConnections. Academic and Community Cancer Research United (ACCRU) continues to expand our portfolio of cancer treatment
Connections Vol. 7 No. 1 Spring 2017 Inside this issue Meeting news...2 Spring ACCRU Scientific Program Overview ACCRU to exhibit at ASCO 2017 Membership news...2 Top accruing members ACCRU welcomes new
More informationTuesday 25th October
14.00-1700 Tuesday 25th October Registration Open 17.00-19.30 Welcome Reception Wednesday 26th October 1 In Situ Disease and Screening Current Perspectives on the Classification and Significance of In
More informationArmstrong, Bruce (Prof.)
Presenter: Armstrong, Bruce (Prof.) Title of Lecture: Cancer Control Research COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been reproduced and communicated to you by or
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationAn Overview of Disparities Research in Access to Radiation Oncology Care
An Overview of Disparities Research in Access to Radiation Oncology Care Shearwood McClelland III, M.D. Department of Radiation Medicine Oregon Health & Science University Portland, Oregon Disclosures
More informationThe Intermountain Oncology Clinical Program: Present and Future
The Intermountain Oncology Clinical Program: Present and Future William T. Sause, MD Director of Radiation Oncology; Intermountain Healthcare; Murray, Utah Objectives: Define current status of the Cancer
More informationSCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017
Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationFrontiers in PREVENTION. Research November 7-10, 2010 Pennsylvania Convention Center Philadelphia, PA
N I N T H A N N UA L A A C R I N T E R N AT I O N A L CO N F E R E N C E Frontiers in CANCER PREVENTION PROGRAM AND PROCEEDINGS November 7-10, 2010 Pennsylvania Convention Center Philadelphia, PA Continuing
More informationOnline/Self study courses
Online/Self study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More informationManaging Older Patients With Lymphoma and Multiple Myeloma
2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to
More informationMerck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor Relations:
More informationTargeted Therapies For Renal Cell Carcinoma
Targeted Therapies For Renal Cell Carcinoma If searched for the ebook Targeted Therapies for Renal Cell Carcinoma in pdf form, in that case you come on to the correct site. We presented utter option of
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationPELVIC MRI COURSE. November 12-14, 2016
Memorial Sloan Kettering Cancer Center is pleased to announce: PELVIC MRI COURSE November 12-14, 2016 Conference Location: Memorial Sloan Kettering Cancer Center Rockefeller Research Laboratories 430 East
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationNRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA (REVISED) Manchester Grand Hyatt San Diego, California February 5 8, 2015
Thursday, February 5, 2015 6:30 am 8:30 am Symposium Breakfast Harbor D-F/2 nd FL 7:00 am 6:00 pm Registration/CME/Information Desk Harbor Foyer/2 nd FL 9:30 am 10:00 am Symposium Coffee Break Harbor D-F/2
More informationJuly 2018 COMPREHENSIVE CANCER CENTER. Coming Up! July Forge Breast Cancer Retreat. July 28 Men at Risk Symposium. And so much more!
COMPREHENSIVE CANCER CENTER Coming Up! July 21 22 Forge Breast Cancer Retreat July 28 Men at Risk Symposium And so much more! July 2018 Follow Us! Facebook: UAB Comprehensive Cancer Center Sunday Monday
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationOnline/Self-study courses
Online/Self-study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More informationACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationNRG ONCOLOGY SEMIANNUAL MEETING PRELIMINARY AGENDA Phoenix Convention Center Phoenix, Arizona February 7 9, 2019
Thursday, February 7, 2019 6:30 am 7:30 am Introduction to Clinical Trials: Principles of Clinical Trial Management Breakfast 7:00 am 8:30 am Symposium Breakfast 7:00 am 6:00 pm Registration/CME/Information
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer
2006 ONS Congress Webcast Evaluation Form Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer Session length: 1 hour, 49 minutes Contact hours: 1.6 Pharmacology hours offered:
More information2017 CANCER COMMITTEE ANNUAL REPORT
2017 CANCER COMMITTEE ANNUAL REPORT steliz.org Chairman s Message The Cancer Committee at HSHS St. Elizabeth s Hospital had diligently worked to improve the care and outcomes of cancer patients throughout
More information2016 SUMMER RESEARCH CONFERENCE AUA/SBUR 2016 SUMMER RESEARCH CONFERENCE. Targeting Epigenetics and Genome Regulation to Improve Urologic Health
2016 SUMMER RESEARCH CONFERENCE AUA/SBUR 2016 SUMMER RESEARCH CONFERENCE Targeting Epigenetics and Genome Regulation to Improve Urologic Health AUA Headquarters Linthicum, MD JULY 16-17, 2016 Understanding
More information3 rd Berlin Cancer Retreat - Agenda
3 rd Berlin Cancer Retreat - Agenda Wednesday, 5 October 2016 8:30 9:00 Registration 9:00 9:10 Welcome and Introduction Program Exploitation of Oncogenic Mechanisms Ulrike Stein 9:10 9:25 Targeting Myc
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationAre the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018 Wednesday, October 17, 2018 8:00 8:30 AM Registration and Continental
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationPELVIC MRI COURSE. November 12-14, 2016
Memorial Sloan Kettering Cancer Center is pleased to announce: PELVIC MRI COURSE November 12-14, 2016 Conference Location: Memorial Sloan Kettering Cancer Center Rockefeller Research Laboratories 430 East
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationFOCUS ON NEUROENDOCRINE TUMORS 7 TH ANNUAL. Friday, April 13, am 2 pm. REGISTER ONLINE AT PennMedicine.org/Abramson/NETs
DEDICATED TO CURING NEUROENDOCRINE CANCER 7 TH ANNUAL FOCUS ON NEUROENDOCRINE TUMORS A PATIENT AND CAREGIVER PROGRAM Friday, April 13, 2018 8 am 2 pm REGISTER ONLINE AT PennMedicine.org/Abramson/NETs Attend
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 25-27, 2017
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 25-27, 2017 Wednesday, October 25, 2017 7:30 8:30 AM Registration
More informationMaking a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION:
Making a Difference Highest quality care. Education. Research. Innovation. OUR MISSION: To deliver world-class care on a daily basis to our patients using the most advanced technologies available. To conduct
More informationILNA Points REFERENCE GUIDE
Learn and Earn With ONS Nursing Education REFERENCE GUIDE Resources for AOCNP and AOCNS Renewal About ILNA The Individual Learning Needs Assessment (ILNA) method is the certification renewal process launched
More informationPeter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective
第 53 回日本癌治療学会学術集会 ASCO, ESMO, ECCO からの招聘演者と講演予定 Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective Ralf A. Stahel (President
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More information2016 Oncology Institute Annual Report
2016 Oncology Institute Annual Report Message from the Cancer Committee: On behalf of the Cancer Committee of The Methodist Hospitals, we are pleased to present to you our 2016 Oncology Institute Annual
More informationPhysical Activity and Cancer
Recent Results in Cancer Research 186 Physical Activity and Cancer Bearbeitet von Kerry S. Courneya, Christine M. Friedenreich 1st Edition. 2010. Buch. xiii, 387 S. Hardcover ISBN 978 3 642 04230 0 Format
More informationJanuary 10-12, Westin Harbour Castle Toronto, ON #CUOS19. cuos2019.org
January 10-12, 2019 Westin Harbour Castle Toronto, ON #CUOS19 cuos2019.org Scientific Program Committee Co-Chairs: Neil Fleshner, CUOG Aly-Khan Lalani, GUMOC Himu Lukka, GUROC Andy Evans, CNUP Tony Finelli,
More informationDr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah
Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss
More informationA PHASE 1 STUDY OF TRC105 (ANTI- ADVANCED SOLID TUMORS
ASCO 2011 Abstract Number: 3073 A PHASE 1 STUDY OF TRC105 (ANTI- CD105 ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, D.
More information